{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:58:31Z","timestamp":1785761911909,"version":"3.56.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001043","name":"Cass Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02296-7","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:33:01Z","timestamp":1778182381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling"],"prefix":"10.1186","volume":"28","author":[{"given":"Alastair A. E.","family":"Saunders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie A.","family":"Mouchemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vojtech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren S.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lap Hing","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gregorevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"6","key":"2296_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2296_CR2","doi-asserted-by":"publisher","first-page":"R44","DOI":"10.1186\/bcr2331","volume":"11","author":"M Kalager","year":"2009","unstructured":"Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res. 2009;11(4):R44.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2296_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien V, De Caluwe A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7.","journal-title":"NPJ Breast Cancer"},{"key":"2296_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/tbcr-24-38","volume":"6","author":"K Jiang","year":"2025","unstructured":"Jiang K, Wang S. Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review. Transl Breast Cancer Res. 2025;6:9.","journal-title":"Transl Breast Cancer Res"},{"key":"2296_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-014-3112-6","volume":"147","author":"L Chen","year":"2014","unstructured":"Chen L, Linden HM, Anderson BO, Li CI. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat. 2014;147:609\u201316.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2296_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619\u201326.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"20","key":"2296_CR7","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271\u20137.","journal-title":"J Clin Oncol"},{"key":"2296_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"2296_CR9","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1038\/cddis.2012.69","volume":"3","author":"S Madonna","year":"2012","unstructured":"Madonna S, Scarponi C, Pallotta S, Cavani A, Albanesi C. Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis. 2012;3(6):e334.","journal-title":"Cell Death Dis"},{"issue":"5368","key":"2296_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/239167a0","volume":"239","author":"I Gresser","year":"1972","unstructured":"Gresser I, Maury C, Brouty-Boy\u00e9 D. Mechanism of the antitumour effect of interferon in mice. Nature. 1972;239(5368):167\u20138.","journal-title":"Nature"},{"issue":"3","key":"2296_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2296_CR12","doi-asserted-by":"publisher","first-page":"e22339","DOI":"10.4161\/onci.22339","volume":"2","author":"CY Slaney","year":"2013","unstructured":"Slaney CY, Moller A, Hertzog PJ, Parker BS. The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. Oncoimmunology. 2013;2(1):e22339.","journal-title":"Oncoimmunology"},{"issue":"6832","key":"2296_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107\u201311.","journal-title":"Nature"},{"issue":"11","key":"2296_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell\u2013autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301\u20139.","journal-title":"Nat Med"},{"issue":"11","key":"2296_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/2326-6066.CIR-15-0065","volume":"3","author":"J Rautela","year":"2015","unstructured":"Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, et al. Loss of host Type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol Res. 2015;3(11):1207\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"1\u20132","key":"2296_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/08977194.2019.1626378","volume":"37","author":"LH Chi","year":"2019","unstructured":"Chi LH, Burrows AD, Anderson RL. Bone morphogenetic protein signaling in breast cancer progression. Growth Factors. 2019;37(1\u20132):12\u201328.","journal-title":"Growth Factors"},{"issue":"18","key":"2296_CR17","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1158\/0008-5472.CAN-13-3171","volume":"74","author":"Y Cao","year":"2014","unstructured":"Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, et al. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res. 2014;74(18):5091\u2013102.","journal-title":"Cancer Res"},{"issue":"6","key":"2296_CR18","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/0008-5472.CAN-19-0743","volume":"80","author":"BL Eckhardt","year":"2020","unstructured":"Eckhardt BL, Cao Y, Redfern AD, Chi LH, Burrows AD, Roslan S, et al. Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis. Cancer Res. 2020;80(6):1304\u201315.","journal-title":"Cancer Res"},{"issue":"17","key":"2296_CR19","doi-asserted-by":"publisher","first-page":"9160","DOI":"10.3390\/ijms25179160","volume":"25","author":"LH Chi","year":"2024","unstructured":"Chi LH, Redfern AD, Lim Kam Sian TC, Street IP, Burrows AD, Roslan S, et al. BMP4-induced suppression of breast cancer metastasis is associated with inhibition of cholesterol biosynthesis. Int J Mol Sci. 2024;25(17):9160.","journal-title":"Int J Mol Sci"},{"key":"2296_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13402-011-0058-0","volume":"35","author":"HP Naber","year":"2012","unstructured":"Naber HP, Wiercinska E, Pardali E, van Laar T, Nirmala E, Sundqvist A, et al. BMP-7 inhibits TGF-\u03b2-induced invasion of breast cancer cells through inhibition of integrin \u03b2 3 expression. Cell Oncol. 2012;35:19\u201328.","journal-title":"Cell Oncol"},{"issue":"18","key":"2296_CR21","doi-asserted-by":"publisher","first-page":"E2307","DOI":"10.1073\/pnas.1501449112","volume":"112","author":"JM Neugebauer","year":"2015","unstructured":"Neugebauer JM, Kwon S, Kim HS, Donley N, Tilak A, Sopory S, et al. The prodomain of BMP4 is necessary and sufficient to generate stable BMP4\/7 heterodimers with enhanced bioactivity in vivo. Proc Natl Acad Sci USA. 2015;112(18):E2307\u201316.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3951","key":"2296_CR22","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1126\/science.169.3951.1213","volume":"169","author":"RE Krueger","year":"1970","unstructured":"Krueger RE, Mayer GD. Tilorone hydrochloride: an orally active antiviral agent. Science. 1970;169(3951):1213\u20134.","journal-title":"Science"},{"issue":"3951","key":"2296_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.169.3951.1214","volume":"169","author":"GD Mayer","year":"1970","unstructured":"Mayer GD, Krueger RF. Tilorone hydrochloride: mode of action. Science. 1970;169(3951):1214\u20135.","journal-title":"Science"},{"issue":"11","key":"2296_CR24","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1021\/acsomega.0c05996","volume":"6","author":"AC Puhl","year":"2021","unstructured":"Puhl AC, Fritch EJ, Lane TR, Tse LV, Yount BL, Sacramento CQ, et al. Repurposing the ebola and marburg virus inhibitors tilorone, quinacrine, and pyronaridine: in vitro activity against SARS-CoV-2 and potential mechanisms. ACS Omega. 2021;6(11):7454\u201368.","journal-title":"ACS Omega"},{"issue":"2","key":"2296_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01711-17","volume":"62","author":"S Ekins","year":"2018","unstructured":"Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O\u2019Loughlin K et al. Efficacy of tilorone dihydrochloride against ebola virus infection. Antimicrob Agents Chemother. 2018;62(2):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"key":"2296_CR26","unstructured":"Sel\u2019kova EP, Semenenko TA, Nosik NN, Iudina TI, Amarian MP, Lavrukhina LA et al. [Effect of amyxin\u2013a domestic analog of tilorone\u2013on characteristics of interferon and immune status of man]. Zh Mikrobiol Epidemiol Immunobiol. 2001(4):31\u20135."},{"key":"2296_CR27","first-page":"17","volume":"2015","author":"L Velychko","year":"2015","unstructured":"Velychko L, Vit V, Maletskyi A, Bogdanova A. Immunomodulating effect of adjuvant interferon inducers in patients receiving combined photocoagulation\/strontium-90 brachytherapy organ-saving treatment for uveal melanoma. Clin Ophthalmol. 2015;2015:17\u201322.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"2296_CR28","first-page":"411","volume":"35","author":"NP Chizhov","year":"1990","unstructured":"Chizhov NP, Smol\u2019skaia TT, Baichenko PI, Luk\u2019ianova RI, Teslenko VM, Bavra GP, et al. [Clinical research on the tolerance for and the interferon-inducing activity of amiksin]. Vopr Virusol. 1990;35(5):411\u20134.","journal-title":"Vopr Virusol"},{"issue":"1","key":"2296_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3181\/00379727-137-35576","volume":"137","author":"HE Kaufman","year":"1971","unstructured":"Kaufman HE, Centifanto YM, Ellison ED, Brown DC. Tilorone hydrochloride: human toxicity and interferon stimulation. Proc Soc Exp Biol Med. 1971;137(1):357\u2009\u201360.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"2296_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02799-8","volume":"37","author":"S Ekins","year":"2020","unstructured":"Ekins S, Lane TR, Madrid PB. Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond. Pharm Res. 2020;37(4):1\u20138.","journal-title":"Pharm Res"},{"issue":"4","key":"2296_CR31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1165\/rcmb.2012-0201OC","volume":"48","author":"O Lepp\u00e4ranta","year":"2013","unstructured":"Lepp\u00e4ranta O, Tikkanen JM, Bespalov MM, Koli K, Myll\u00e4rniemi M. Bone morphogenetic protein\u2013inducer tilorone identified by high-throughput screening is antifibrotic in vivo. Am J Respir Cell Mol Biol. 2013;48(4):448\u201355.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"605","key":"2296_CR32","doi-asserted-by":"publisher","first-page":"eaay9592","DOI":"10.1126\/scitranslmed.aay9592","volume":"13","author":"R Sartori","year":"2021","unstructured":"Sartori R, Hagg A, Zampieri S, Armani A, Winbanks CE, Viana LR, et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med. 2021;13(605):eaay9592.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2296_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/jcp.30998","volume":"238","author":"ZM Kohler","year":"2023","unstructured":"Kohler ZM, Trencsenyi G, Juhasz L, Zvara A, Szabo JP, Dux L, et al. Tilorone increases glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2\/AS160 signaling and glucose transporter levels. J Cell Physiol. 2023;238(5):1080\u201394.","journal-title":"J Cell Physiol"},{"key":"2296_CR34","doi-asserted-by":"crossref","unstructured":"Horvath B, Halasz J, Tanner NN, Kohler ZM, Trencsenyi G, Juhasz L et al. Tilorone attenuates high-fat diet-induced hepatic steatosis by enhancing BMP9-Smad1\/5\/8 signaling. Geroscience. 2025.","DOI":"10.1007\/s11357-025-01685-8"},{"issue":"5","key":"2296_CR35","doi-asserted-by":"publisher","first-page":"e22246","DOI":"10.1002\/ddr.22246","volume":"85","author":"AS Chhipa","year":"2024","unstructured":"Chhipa AS, Sharma A, Verma S, Patel SS. Therapeutic effects of tilorone on mammary carcinogenesis through downregulation of pro-inflammatory cytokines and oxidative stress. Drug Dev Res. 2024;85(5):e22246.","journal-title":"Drug Dev Res"},{"issue":"4","key":"2296_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/sj.onc.1208204","volume":"24","author":"C Porta","year":"2005","unstructured":"Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, et al. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene. 2005;24(4):605\u201315.","journal-title":"Oncogene"},{"issue":"3","key":"2296_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/1097-0142(19810801)48:3<681::AID-CNCR2820480304>3.0.CO;2-J","volume":"48","author":"FJ Cummings","year":"1981","unstructured":"Cummings FJ, Gelman R, Skeel RT, Kuperminc M, Israel L, Colsky J, et al. Phase II trials of baker\u2019s antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. Cancer. 1981;48(3):681\u20135.","journal-title":"Cancer"},{"issue":"1","key":"2296_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12964-023-01062-y","volume":"21","author":"A Lamsal","year":"2023","unstructured":"Lamsal A, Andersen SB, Johansson I, Vietri M, Bokil AA, Kurganovs NJ, et al. Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. Cell Commun Signal. 2023;21(1):50.","journal-title":"Cell Commun Signal"},{"issue":"7","key":"2296_CR39","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"},{"key":"2296_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1006689719505","volume":"17","author":"M Lelekakis","year":"1999","unstructured":"Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin experimental metastasis. 1999;17:163\u201370.","journal-title":"Clin experimental metastasis"},{"issue":"6","key":"2296_CR41","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399\u2013405.","journal-title":"Cancer Res"},{"issue":"1","key":"2296_CR42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12964-024-01559-0","volume":"22","author":"LH Chi","year":"2024","unstructured":"Chi LH, Redfern AD, Roslan S, Street IP, Burrows AD, Anderson RL. Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling. Cell Commun Signal. 2024;22(1):248.","journal-title":"Cell Communication Signal"},{"issue":"3","key":"2296_CR43","first-page":"735","volume":"49","author":"SC Rockwell","year":"1972","unstructured":"Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972;49(3):735\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"2296_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-007-9761-y","volume":"111","author":"X-Z Chang","year":"2008","unstructured":"Chang X-Z, Li D-Q, Hou Y-F, Wu J, Lu J-S, Di G-H, et al. Identification of the functional role of AF1Q in the progression of breast cancer. Breast cancer Res Treat. 2008;111:65\u201378.","journal-title":"Breast cancer Res Treat"},{"issue":"1","key":"2296_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13058-019-1177-1","volume":"21","author":"A Nagpal","year":"2019","unstructured":"Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+\u2009ve) breast cancer metastasis. Breast Cancer Res. 2019;21(1):94.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2296_CR46","doi-asserted-by":"publisher","first-page":"C1498","DOI":"10.1152\/ajpcell.00230.2025","volume":"329","author":"AAE Saunders","year":"2025","unstructured":"Saunders AAE, Karagiannis C, Du WX, James LS, Thomson RE, Anderson RL, et al. Cachexia progression differs among mouse models of metastatic triple-negative breast cancer. Am J Physiol Cell Physiol. 2025;329(5):C1498\u2013510.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"2296_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"3","key":"2296_CR48","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gyorffy","year":"2010","unstructured":"Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725\u201331.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"2296_CR49","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145","author":"JT Fekete","year":"2019","unstructured":"Fekete JT, Gyorffy B. ROCplot.org: Validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J Cancer. 2019;145(11):3140\u201351.","journal-title":"Int J Cancer"},{"issue":"2","key":"2296_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1128\/AAC.2.2.73","volume":"2","author":"DA Stringfellow","year":"1972","unstructured":"Stringfellow DA, Glasgow LA. Tilorone hydrochloride: an oral interferon-inducing agent. Antimicrob Agents Chemother. 1972;2(2):73\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2296_CR51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/2326-6066.CIR-17-0150","volume":"5","author":"NK Brockwell","year":"2017","unstructured":"Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, et al. Neoadjuvant interferons: critical for effective PD-1-Based immunotherapy in TNBC. Cancer Immunol Res. 2017;5(10):871\u201384.","journal-title":"Cancer Immunol Res"},{"key":"2296_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-019-0093-2","volume":"3","author":"NK Brockwell","year":"2019","unstructured":"Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, et al. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. NPJ Precis Oncol. 2019;3:21.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"2296_CR53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-2567.2011.03446.x","volume":"133","author":"B Fu","year":"2011","unstructured":"Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology. 2011;133(3):350\u20139.","journal-title":"Immunology"},{"issue":"22","key":"2296_CR54","first-page":"5488","volume":"113","author":"L Chiossone","year":"2009","unstructured":"Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood J Am Soc Hematol. 2009;113(22):5488\u201396.","journal-title":"Blood J Am Soc Hematol"},{"key":"2296_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2016.11.015","volume":"72","author":"N Touati","year":"2017","unstructured":"Touati N, Tryfonidis K, Caramia F, Bonnefoi H, Cameron D, Slaets L, et al. Correlation between severe infection and breast cancer metastases in the EORTC 10994\/BIG 1\u2009\u2013\u200900 trial: investigating innate immunity as a tumour suppressor in breast cancer. Eur J Cancer. 2017;72:95\u2013102.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2296_CR56","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18(8):1224\u201331.","journal-title":"Nat Med"},{"issue":"15","key":"2296_CR57","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41388-018-0624-2","volume":"38","author":"Q Lan","year":"2019","unstructured":"Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, et al. Type I interferon\/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene. 2019;38(15):2814\u201329.","journal-title":"Oncogene"},{"key":"2296_CR58","doi-asserted-by":"publisher","first-page":"1200245","DOI":"10.3389\/fimmu.2023.1200245","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Lin M, Zhu L, Ye Z. GAS-STING: a classical DNA recognition pathways to tumor therapy. Front Immunol. 2023;14:1200245.","journal-title":"Front Immunol"},{"key":"2296_CR59","doi-asserted-by":"publisher","first-page":"178249","DOI":"10.1016\/j.ejphar.2025.178249","volume":"1008","author":"AS Chhipa","year":"2025","unstructured":"Chhipa AS, Gallicchio M, Boscaro V, Patel S. Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer. Eur J Pharmacol. 2025;1008:178249.","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"2296_CR60","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1038\/onc.2011.400","volume":"31","author":"J Buijs","year":"2012","unstructured":"Buijs J, Van Der Horst G, Van Den Hoogen C, Cheung H, De Rooij B, Kroon J, et al. The BMP2\/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene. 2012;31(17):2164\u201374.","journal-title":"Oncogene"},{"issue":"4","key":"2296_CR61","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1574-695X.2000.tb01488.x","volume":"28","author":"E Ortega","year":"2000","unstructured":"Ortega E, Algarra I, Serrano MJ, de Pablo MA, Alvarez de Cienfuegos G, Gaforio JJ. Enhanced resistance to experimental systemic candidiasis in tilorone-treated mice. FEMS Immunol Med Microbiol. 2000;28(4):283\u20139.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"3","key":"2296_CR62","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/iub.1985","volume":"71","author":"TN Sharapova","year":"2019","unstructured":"Sharapova TN, Romanova EA, Sashchenko LP, Yashin DV. Tilorone activates NK cells and cytotoxic lymphocytes that kill HLA-negative tumor cells. IUBMB Life. 2019;71(3):376\u201384.","journal-title":"IUBMB Life"},{"issue":"1","key":"2296_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF01784331","volume":"12","author":"I Algarra","year":"1994","unstructured":"Algarra I, Perez M, Gaforio JJ, Gasca F, Garrido F. In vivo activation of NK cells induces inhibition of lung colonization of H-2 positive and H-2 negative fibrosarcoma tumor clones. Clin Exp Metastasis. 1994;12(1):31\u20136.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"2296_CR64","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2249.1996.tb08308.x","volume":"103","author":"I Algarra","year":"1996","unstructured":"Algarra I, Gonzalez A, Perez M, Gaforio JJ, Garrido F. Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Clin Exp Immunol. 1996;103(3):499\u2013505.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"2296_CR65","first-page":"2799","volume":"44","author":"PS Sunkara","year":"1984","unstructured":"Sunkara PS, Prakash NJ, Rosenberger AL, Hagan AC, Lachmann PJ, Mayer GD. Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers. Cancer Res. 1984;44(7):2799\u2013802.","journal-title":"Cancer Res"},{"issue":"1","key":"2296_CR66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3892\/or.2014.3174","volume":"32","author":"MD Wissing","year":"2014","unstructured":"Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, et al. Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol Rep. 2014;32(1):419\u201324.","journal-title":"Oncol Rep"},{"issue":"4","key":"2296_CR67","first-page":"181","volume":"11","author":"J Stratton","year":"1983","unstructured":"Stratton J, Rettenmaier M, DiSaia P. In vivo antineoplastic activity of various biological response modifiers for tumors of the ovary and breast. J Clin Lab Immunol. 1983;11(4):181\u20137.","journal-title":"J Clin Lab Immunol"},{"issue":"1","key":"2296_CR68","first-page":"44","volume":"27","author":"WA Basley","year":"1981","unstructured":"Basley WA, Rees RC, Greager JA, Baldwin RW. Antitumour effects of tilorone hydrochloride on the in vivo growth of chemically induced and spontaneously arising rat tumours. Chemotherapy. 1981;27(1):44\u201352.","journal-title":"Chemotherapy"},{"issue":"10","key":"2296_CR69","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41590-024-01960-4","volume":"25","author":"NM Haynes","year":"2024","unstructured":"Haynes NM, Chadwick TB, Parker BS. The complexity of immune evasion mechanisms throughout the metastatic cascade. Nat Immunol. 2024;25(10):1793\u2013808.","journal-title":"Nat Immunol"},{"issue":"1","key":"2296_CR70","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/jitc-2019-000491","volume":"8","author":"S Garcia-Mulero","year":"2020","unstructured":"Garcia-Mulero S, Alonso MH, Pardo J, Santos C, Sanjuan X, Salazar R et al. Lung metastases share common immune features regardless of primary tumor origin. J Immunother Cancer. 2020;8(1):e000491.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2296_CR71","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2016.10.010","volume":"49","author":"SJ Luen","year":"2017","unstructured":"Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017;49(2):141\u201355.","journal-title":"Pathology"},{"issue":"1","key":"2296_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41523-022-00486-y","volume":"8","author":"Y Abdou","year":"2022","unstructured":"Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. NPJ Breast Cancer. 2022;8(1):121.","journal-title":"NPJ Breast Cancer"},{"key":"2296_CR73","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ejmech.2013.03.050","volume":"64","author":"D Zhou","year":"2013","unstructured":"Zhou D, Tuo W, Hu H, Xu J, Chen H, Rao Z, et al. Synthesis and activity evaluation of tilorone analogs as potential anticancer agents. Eur J Med Chem. 2013;64:432\u201341.","journal-title":"Eur J Med Chem"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02296-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:24:50Z","timestamp":1782879890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02296-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2296"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02296-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were conducted in accordance with the relevant code of practice for the care and use of animals for scientific purposes (National Health and Medical Research Council of Australia) and were approved by the University of Melbourne Animal Ethics Committee (ethics #24412) or by the Animal Ethics Committee at the Peter MacCallum Cancer Centre (ethics #2023-29).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}